Fitness Trends Fc Protein and Glycoengineered Antibodies Market

Fc Protein and Glycoengineered Antibodies
Market – Size, Share, Outlook, and Opportunity
Analysis, 2019 – 2027
Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use.
The crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next
generation antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of
molecules, which are attached to a glycan residue on crystallisable fragment. Glycoengineering
is the method by which these antibodies are created. They have varied applications for the
treatment of diseases such as multiple sclerosis and cancers.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2626
Global Fc Protein and Glycoengineered Antibodies Market Drivers
Key players in the market are focusing on research and development activities and receiving
approvals from regulatory bodies, which are expected to boost the global Fc protein and
glycoengineered antibodies market growth over the forecast period.
For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug
Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of
urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA
for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc.
began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in
third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline
are expected to drive the global fc protein and glycoengineered antibodies market growth.
Increasing prevalence of diseases such as cancer is expected to propel the global Fc protein and
glycoengineered antibodies market growth. According to the World Health Organization (WHO),
cancer is considered as the second most leading cause of death worldwide, and, in 2018,
around 9.6 million people died worldwide due to cancer. Hence, glycoengineered antibodies can
be developed for the treatment of cancer and thus, this factor is expected to drive growth of
the global fc protein and glycoengineered antibodies market over the forecast period.